Thalidomide

SKU: orb1310829

Description

Thalidomide is a synthetic glutamic acid derivative with known teratogenic effects. It is widely used in research for its immunomodulatory, anti-inflammatory, and anti-angiogenic properties, applicable in both in vitro and in vivo studies of cancer, autoimmune diseases, and angiogenesis.

Research Area

Immunology & Inflammation, Protein Biochemistry

Key Properties

• CAS Number: 50-35-1
• MW: 258.3
• Purity: >98%
• Formula: C₁₃H₁₀N₂O₄
• SMILES: O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2
• Target: Ubiquitin ligase
• Solubility: Soluble in DMSO (up to 5 mg/ml).

Bioactivity

• Target IC50:
  CRL4CRBN:250 nM (Kd)
• In Vivo:
  Administering 200mg/kg of Thalidomide resulted in the inhibition of vascularization in the corneal region within rabbits, with the inhibition rate ranging from 30% to 51% across three experiments.
  Read more...
• In Vitro:
  Thalidomide selectively inhibits the production of tumor necrosis factor-alpha (TNF-α) in human monocytes stimulated by lipopolysaccharides and other agonists. Its suppression of TNF-α is mediated through the enhancement of mRNA degradation. Moreover, thalidomide exerts a direct effect on MM cell lines by inducing apoptosis and G1 phase growth arrest, as well as on patient MM cells resistant to melphalan, doxorubicin hydrochloride, and dexamethasone.
  Read more...

Storage & Handling

• Storage: RT
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Sedoval, Thalomid, TNF-α, Thalidomide, Molecular Glues, MolecularGlues, Ligand for E3 Ligase, LigandforE3Ligase, Ligands for E3 Ligase, inhibit, Inhibitor, E3 ligase-recruiting Moiety, Apoptosis, Autophagy

Compound Identifiers

PubChem CID

5426